<DOC>
	<DOCNO>NCT01517568</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial characterise metabolic profile liraglutide plasma , urine , faeces single injection [ 3H ] -liraglutide .</brief_summary>
	<brief_title>Metabolism Excretion Liraglutide Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Good general health judge Investigator , base medical history , physical examination include 12lead ECG ( electrocardiogram ) , vital sign , blood urinary laboratory assessment BMI ( Boday Mass Index ) 20.027.0 kg/m^2 , inclusive History clinically significant renal , hepatic , cardiovascular , pulmonary , gastrointestinal , metabolic , endocrine , haematological , neurological , psychiatric disease major disorder may interfere objective trial , judge Investigator Impaired renal function Active hepatitis B active hepatitis C Positive human immunodeficiency virus ( HIV ) antibodies Any clinically significant abnormal ECG , judge Investigator Any clinically significant abnormal laboratory test result , judge Investigator Acute infection inflammation illness may influence metabolism excretion pattern trial product , judged Investigator Known suspect allergy trial product ( ) relate product History alcoholism drug abuse positive result alcohol drug screen Smoking 5 cigarette per day Habitual excessive consumption methylxanthinecontaining ( theophylline , caffeine theobromine ) beverages food ( coffee , tea , soft drink red bull , cola , chocolate ) judge Investigator Excessive consumption diet deviate normal diet , judge Investigator</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>